• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sagimet Biosciences Inc. - Series A Common Stock (NQ:SGMT)

9.060 -0.560 (-5.82%)
Delayed Quote Updated: 3:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 805,258
Open 9.320
Bid (Size) 9.050 (500)
Ask (Size) 9.070 (400)
Prev. Close 9.620
Today's Range 8.832 - 9.400
52wk Range 4.500 - 11.45
Shares Outstanding 30,674,855
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
November 12, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 29, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire

Performance

52-Week Range 20.9% below 52-week high
9.060
4.5052W Low 11.4552W High
1 Week 16.4% below 1-week high
9.571W Low 10.841W High

Sagimet Biosciences Inc. - Series A Common Stock (SGMT) traded between $4.50 and $11.45 over the past 52 weeks and last traded at $9.06, 20.9% below its 52-week high. Over the past week it ranged between $9.57 and $10.84.

Past 12 Months
-11.4%
-7.0%
-11.0%
+29.4%
+51.3%
+15.4%
1W -$1.16
1M -$0.68
3M -$1.12
6M +$2.06
YTD +$3.07
1Y +$1.21

SGMT was +15.4% over the past year, +29.4% over six months, +51.3% year to date, -11.4% in the last week.

12 Months vs Market
SGMT
+15.4%
DIA
+4.8%
SPY
+4.9%
QQQ
+2.5%
IWM
+10.6%

Over the past 12 months SGMT returned +15.4% versus DIA (Dow) +4.8%, SPY (S&P 500) +4.9%, QQQ (Nasdaq 100) +2.5% and IWM (Russell 2000) +10.6%.

Volume & Liquidity 0.66× 3-mo avg
Today 805,258 3-mo avg 1.2M
1W
917.3K
1M
1.1M
3M
1.2M
6M
1.2M
YTD
1.2M
1Y
1.1M

SGMT most recently traded 805,258 shares against a 3-month average daily volume of 1.2M.

More News

Read More
News headline image
Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
October 22, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
October 09, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch ↗
October 03, 2026
Via MarketBeat
News headline image
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
October 01, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
September 30, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
September 30, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
September 28, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
September 02, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
August 25, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data ↗
August 17, 2026
Via MarketBeat
News headline image
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
August 13, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
August 11, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 04, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
June 29, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 22, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
May 27, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 13, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 12, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
May 11, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
Unusual volume stocks are being observed in Tuesday's session. ↗
April 28, 2026
Via Chartmill
These stocks are moving in today's session ↗
April 27, 2026
Via Chartmill
Top stock movements in today's session. ↗
April 27, 2026
Via Chartmill

Frequently Asked Questions

Is Sagimet Biosciences Inc. - Series A Common Stock publicly traded?
Yes, Sagimet Biosciences Inc. - Series A Common Stock is publicly traded.
What exchange does Sagimet Biosciences Inc. - Series A Common Stock trade on?
Sagimet Biosciences Inc. - Series A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock?
The ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock is SGMT on the Nasdaq Stock Market
What is the current price of Sagimet Biosciences Inc. - Series A Common Stock?
The current price of Sagimet Biosciences Inc. - Series A Common Stock is 9.060
When was Sagimet Biosciences Inc. - Series A Common Stock last traded?
The last trade of Sagimet Biosciences Inc. - Series A Common Stock was at 11/20/26 03:00 PM ET
What is the market capitalization of Sagimet Biosciences Inc. - Series A Common Stock?
The market capitalization of Sagimet Biosciences Inc. - Series A Common Stock is 277.91M
How many shares of Sagimet Biosciences Inc. - Series A Common Stock are outstanding?
Sagimet Biosciences Inc. - Series A Common Stock has 278M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap